After five years of dedicated research, doctors at a hospital in Guangdong province have developed the world's first arginine-based polymer drug delivery system that preserves the complete structure of the intervertebral disc.
Led by Wei Fuxin, a professor at the Seventh Affiliated Hospital of Sun Yat-sen University, the research team has discovered a technology that takes an unconventional approach.
Instead of injecting the drug directly into the front of the intervertebral disc, it enters through the "back door" via the sub-endplate bone of the vertebral body, according to Wei.
Utilizing the strong positive charge adsorption capability of the arginine polymer, it navigates through the bone tissue with precision to reach the site of the disc lesion.
"Like a smart GPS, injection of the drug ultimately achieves anti-inflammatory effects and relieves back pain," Wei said, adding the outer fibrous ring of the disc remains intact throughout the injection process.
For a long time, injecting medication directly into the intervertebral disc can puncture the jelly-like outer shell, which will accelerate its degeneration. However, without administering medication, inflammation and pain cannot be effectively controlled.
"The answer behind the technology breakthrough is the arginine polymer," Wei said.
The polypeptide chain, composed of multiple arginine residues, carries a strong positive charge.
"It not only penetrates cellular barriers, but also promotes collagen synthesis, regulates cell metabolism, and exhibits anti-inflammatory and antioxidant properties, aiding in tissue self-repair," Wei said.
Data shows that compared to traditional anti-inflammatory drugs, the intervention group using the arginine polymer had a 31.7 percent higher relief rate for discogenic low back pain.
Currently, the research has entered the clinical trial phase, offering a new treatment option for the early intervention of degenerative spinal diseases.
(Cover image: Guangzhou Daily)
